[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-371717-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-371717-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","distal-covalent-targeting-suppresses-signaling-of-oncogenic-k-rasg13c-in-cancer-cells","Distal Covalent Targeting Suppresses Signaling of Oncogenic K-Ras(G13C) in Cancer Cells","","Oncogenic Ras mutations drive frequent cancer disease burden, yet direct binding ligands that block downstream signaling were long absent because Ras lacks obvious drug binding pockets. Approved K-Ras inhibitors rely on covalent recognition of the highly nucleophilic Cys residue in K-Ras(G12C), while noncovalent G13C binders lack mutant specificity. This study reports targeted electrophiles covalently modifying Cys13 in KRas(G13C), overcoming the shifted Cys13 position. The inhibitors alkylate both GDP- and GTP-bound KRas(G13C), disrupt effector interactions, and suppress growth of KRas(G13C)-mutation cancer cells. Results broaden covalent K-Ras strategies beyond G12-driven disease toward K-Ras(G13C)-driven tumors.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/distal-covalent-targeting-suppresses-signaling-of-oncogenic-k-rasg13c-in-cancer-cells/371717/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/distal-covalent-targeting-suppresses-signaling-of-oncogenic-k-rasg13c-in-cancer-cells/371717.png","ImageObject",300,407,{"name":42,"@type":43},"Stanford","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why were direct Ras binding ligands difficult to develop before 2013?","Question",{"text":63,"@type":64},"Ras was considered hard to drug due to the lack of obvious drug binding pockets, preventing direct binding ligand development until later breakthroughs.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do the reported inhibitors specifically target K-Ras(G13C)?",{"text":68,"@type":64},"The study designs targeted electrophiles to covalently modify Cys13 in KRas(G13C), addressing the structural challenge caused by the shifted position relative to Cys12 in K-Ras(G12C).",{"name":70,"@type":61,"acceptedAnswer":71},"What biological effects do the covalent inhibitors produce?",{"text":72,"@type":64},"They alkylate KRas(G13C) in both GDP- and GTP-bound states, block effector interactions, and suppress the growth of cancer cell lines carrying KRas(G13C) mutations.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},371717,1790901458,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336477552062,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","This article is licsisertuileiClie-sYe-dNeDr . -BY 4.0   \n[pubs.acs.org/acschemicalbiology](pubs.acs.org/acschemicalbiology)  Article   \nDistal Covalent Targeting Suppresses Signaling of Oncogenic K‑Ras(G13C) in Cancer Cells  \nQinheng Zheng,∥ Tianfang Shen,∥ Julius Pampel, and Kevan M. Shokat *  \n Cite This: ACS Chem. Biol. 2025, 20, 1696−1706  \nRead Online  \n\n|  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- |\n| ACCESS   | Metrics & More |  |  Article Recommendations |  | *sı Supporting Information |\n\nABSTRACT: Oncogenic mutations of Ras are among the most common genetic alterations in human cancer, with an estimated disease burden of >3 million new patients per year worldwide. Despite widespread appreciation of the importance of Ras in cancer, direct binding ligands, which block downstream signaling, were not reported until 2013 due to the lack of obvious drug binding pocketsin the protein. The clinically approved K-Ras inhibitors are mutantselective as they rely on covalent recognition of the highly nucleophilic somatic cysteine residue of K-Ras(G12C). Recent preclinical reports of noncovalent K-Ras binding inhibitors have emerged, which lack mutant specificity and exhibit varying degrees of biochemical preference for mutant K-Ras over the wild-type. An  \nadjacent glycine-13 mutation, p. G13C, particularly abundant in lung, colorectal, and pancreatic cancer, has not been targeted with an approved therapeutic molecule. Here, we report a series of targeted electrophiles designed to covalently modify Cys13 in KRas(G13C), overcoming the structural challenge posed by its shifted position relative to Cys12 in K-Ras(G12C). These inhibitors effectively alkylate K-Ras(G13C) in both GDP- and GTP-bound states, block effector interactions, and suppress the growth of KRas(G13C)-mutation cancer cell lines. Our findings expand the landscape of covalent K-Ras inhibitors beyond G12 mutations, providing a new therapeutic strategy for K-Ras(G13C)-driven cancers.  \nK-Ras is the most frequently mutated oncogene in human cancer, with approximately 20% of newly diagnosed cancer patients harboring a K-Ras mutation. These mutations are particularly enriched in pancreatic ductal adenocarcinoma (76%), colon adenocarcinoma (40%), and nonsmall cell lung carcinoma (26%). 1−3 Missense substitution, most commonly at G12 (81%), G13 (14%), and Q61 (2%), drives oncogenic activation K-Ras.4,5  \nFor decades, K-Ras was considered an “undruggable” target6 due to the lack of accessible binding pockets and the high structural similarity between mutant and wild-type forms. Characterization of the cryptic Switch-II Pocket7 sparked the development of the first FDA-approved small-molecule inhibitors, sotorasib8,9 and adagrasib, 10 to treat K-Ras(G12C) mutation-driven nonsmall cell lung cancer.  \nThe K-Ras(G13C) mutation is the second most common G13 mutation, frequently found in lung, colorectal, and pancreatic tumors.5 Like other hotspot mutations of Ras protein, G13C impairs intrinsic and p120-RasGAP-mediated GTP hydrolysis compared to wild-type (WT).11, 12 However, K-Ras(G13C) and the related G13D mutations are biochemically distinct from the G12 or Q61 mutations. Notably, G13C/ D mutations remain sensitive to NF1-mediated GTP hydrolysis, and NF1 loss-of-function commutation is a signature in K-Ras(G13C/D) mutation patients.12, 13 Additionally, K-Ras(G13C) exhibits a rapid nucleotide exchange,  \nenriching it in the active GTP-bound state. A study using isogenic MCF10A cells suggested that K-Ras(G13C) is highly enriched in its GTP-bound form compared to other hotspot mutations but is less transforming than G12D, G12 V, or G13D.14  \nTo date, no targeted therapies are available for KRas(G13C) mutation patients. The lack of bioavailable, mutant-selective inhibitors is further compounded by the high comutation frequency of STK11 and KEAP1 in KRas(G13C) mutation patients, which correlate with poor responses to immune checkpoint inhibitors (2.1% progressionfree surv","cbCaih3gxl3wXRcM","https://ap.wps.com/l/cbCaih3gxl3wXRcM","pdf",5930119,11,"English","# Abstract\n## Covalent inhibitor design for KRas(G13C)\n## Mechanistic activity across nucleotide states\n## Biological impact on cancer cell growth\n## Broader implications beyond G12 mutations","[{\"question\":\"Why were direct Ras binding ligands difficult to develop before 2013?\",\"answer\":\"Ras was considered hard to drug due to the lack of obvious drug binding pockets, preventing direct binding ligand development until later breakthroughs.\"},{\"question\":\"How do the reported inhibitors specifically target K-Ras(G13C)?\",\"answer\":\"The study designs targeted electrophiles to covalently modify Cys13 in KRas(G13C), addressing the structural challenge caused by the shifted position relative to Cys12 in K-Ras(G12C).\"},{\"question\":\"What biological effects do the covalent inhibitors produce?\",\"answer\":\"They alkylate KRas(G13C) in both GDP- and GTP-bound states, block effector interactions, and suppress the growth of cancer cell lines carrying KRas(G13C) mutations.\"}]","Distal Covalent Targeting Suppresses Signaling of Oncogenic K-Ras(G13C) in Cancer Cells | PDF",1790192693,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b85ffc3363029727e723022215773493.webp",983,1296,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/636e8c35ff5325c074e42bad708bd9f5.webp",982,1295,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6cf7659ba350ebb6fc26e5fc41b8347e.webp",981,1293,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e589a8f9e12940a4972311f7f7375f18.webp",980,1292]